2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5697 Fto-mediated epitranscriptomic silencing of MT2A promotes multiple myeloma progression by activating JNK/p38 MAPK signaling

Wanting Yu, MD, Aoshuang Xu, MD2, Hu Yu, MD3, Chunyan Sun, MD4
1 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
2 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
3 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
4 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China

INTRODUCTION:
Metallothionein 2A (MT2A) maintains metal ion homeostasis and supports cellular adaptation to stress. Although dysregulated MT2A expression has been implicated in several malignancies, its biological role in multiple myeloma (MM) remain unclear. We investigated the clinical relevance and biological function of MT2A in MM and defined its downstream signaling and upstream epitranscriptomic regulation.

METHODS: MT2A expression in MM cell lines and patient-derived samples was assessed by RT-qPCR, western blotting, and immunohistochemistry. Associations between MT2A expression, clinical features, and survival were analyzed using Cox regression. The biological effects of MT2A overexpression and knockdown were evaluated using CCK-8, colony-formation, Transwell, and flow cytometric assays. Downstream signaling was investigated by RNA sequencing, pathway enrichment analysis, western blotting, and functional rescue experiments, with in vivo validation in a subcutaneous MM xenograft model established in NOD/SCID mice. Public proteomic data were used to identify candidate upstream regulators, followed by validation using RIP-qPCR. The mechanism of MT2A downregulation was further investigated by integrating RNA sequencing and MeRIP-seq after FTO overexpression or knockdown, followed by MeRIP-qPCR and RNA stability assays.

RESULTS: MT2A was significantly downregulated in MM cell lines and primary MM cells. Low MT2A expression was associated with advanced International Staging System (ISS) and Revised ISS (R-ISS) stages, a higher proportion of immature bone marrow plasma cells, and elevated β2-microglobulin, lactate dehydrogenase, and serum calcium levels. Multivariable analysis identified low MT2A expression as an independent risk factor for shorter progression-free survival (PFS) and overall survival (OS). MT2A overexpression suppressed MM cell proliferation, migration, invasion, and colony formation while promoting apoptosis in vitro, whereas MT2A knockdown produced the opposite effects. Transcriptomic and pathway enrichment analyses implicated MAPK signaling in MT2A-mediated tumor suppression. MT2A overexpression selectively reduced the phosphorylation of JNK and p38 MAPK, with minimal effects on ERK. Silencing JNK and p38 attenuated the tumor-promoting phenotypes induced by MT2A loss. Consistently, MT2A overexpression inhibited MM xenograft growth and reduced phosphorylated JNK and p38 levels in vivo. MT2A pre-RNA levels remained unchanged, suggesting post-transcriptional regulation. N6-methyladenosine (m6A) sites within MT2A transcripts exhibited reduced methylation in MM cells. Public proteomic datasets showed increased expression of the m6A demethylases FTO and ALKBH5 in MM. RIP-qPCR demonstrated that FTO, but not ALKBH5, associated with MT2A transcripts. Integrated RNA sequencing and MeRIP-seq following FTO overexpression or knockdown further identified MT2A as an FTO target. FTO-mediated m6A demethylation impaired IGF2BP1-dependent stabilization of MT2A mRNA, accelerated transcript decay, and consequently reduced MT2A expression.

CONCLUSION: MT2A was downregulated in MM, and low MT2A expression was independently associated with shorter PFS and OS. Mechanistically, FTO-mediated m6A demethylation of MT2A transcripts impaired IGF2BP1-dependent mRNA stabilization and accelerated transcript decay, resulting in epitranscriptomic repression of MT2A. MT2A loss subsequently activated JNK/p38 MAPK signaling and promoted MM progression. Collectively, these findings define an FTO-MT2A-JNK/p38 MAPK regulatory axis that contributes to MM progression and provide a mechanistic rationale for developing therapeutic strategies targeting this axis.

Wanting Yu, MD: No relevant conflicts of interest to declare.